Drug Database
ES

estradiol + levonorgestrel (Nuvelle TS / Climara Duo)

✓ Approved

Elan · ESR1 · Small Molecule

What is estradiol + levonorgestrel?

estradiol + levonorgestrel is a small molecule developed by Elan. It is approved for therapeutic indications via topical or transdermal.

Drug Profile

Brand NamesNuvelle TS, Climara Duo
CompanyElan
Drug ClassSmall Molecule
Molecular TargetESR1, PGR
RouteTopical, Transdermal
StatusApproved

Mechanism of Action

Molecular Targets

estradiol + levonorgestrel acts on 2 molecular targets:

ESR1estrogen receptor 1 (ER, ESR)
PGRprogesterone receptor (NR3C3, PR)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

estradiol + levonorgestrel is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Surgical and medical proceduresHormone replacement therapy✓ Approved

Related Research Articles

PubMedThe Journal of clinical endocrinology and metabolism2026-10-07

Biallelic CYB5A disruptions in 46, XY DSD: Novel missense and deep intronic variants.

Moradifard Shirin S, Le Thanh Nha Uyen TNU, Ha Nguyen Thu NT, Dung Vu Chi VC et al.

Cytochrome b5, encoded by CYB5A, is an essential co-factor for CYP17A1-mediated 17,20-lyase activity. CYB5A deficiency is a rare cause of 46,XY DSD. We report two siblings with 46,XY DSD from a Vietnamese family, presenting with phenotypic female. Clinical evaluation and hormone profiling were conducted. Whole genome sequencing (WGS) was performed on extracted DNA from both affected siblings and identified variants were classified according to the ACMG/AMP 2015 guidelines. A minigene RNA splicing assay in HEK293T cells was used to evaluate the functional impact of the CYB5A intronic variant. The two patients' hormone profile showed low testosterone and estradiol. WGS identified novel compound heterozygous CYB5A variants: a paternally inherited missense variant (p.Val34Glu) and a maternally inherited deep intronic deletion (c.129 + 862_129 + 863del) which predicted to create the cryptic splice sites by SpliceAI. Minigene assays confirmed the activation of the cryptic splice sites, resulting in an inclusion of a pseudo-exon between exon 1 and 2. This aberrant insertion introduced a premature stop codon, leading to predicted nonsense-mediated decay of the transcript. Both variants were classified as likely pathogenic according to the ACMG/AMP guideline. Two novel CYB5A variants established the genetic diagnosis in both siblings, expanding the spectrum of pathogenic CYB5A-related DSD. Our findings show that a deep intronic variant can lead to null protein due to disrupted splicing. These results highlight the value of WGS and functional assays for detecting and validating clinically relevant non-coding variants in DSD.

PubMedEnvironmental science and pollution research international2026-10-07

Competitive adsorption of natural and synthetic estrogens onto sustainable almond-shell and cork residues: kinetics, multi-component isotherms, and mechanism analysis.

Exposto Bruno M BM, Gomes Maria Carolina Sergi MCS, de Menezes Maraísa Lopes ML, Brito Paulo P et al.

This study investigates the competitive removal of three co-existing estrogens, estrone (E1), 17β-estradiol (E2), and 17α-ethinylestradiol (EE2), from aqueous matrices via batch adsorption. Pre- and post-carbonized materials synthesized from industrial almond shell and cork residues were evaluated under multicomponent conditions. Thermal activation via carbonization proved ineffective, whereas raw cork ("in natura," CiN) exhibited the optimal performance. At 25 °C and an adsorbent dosage of 1.0 g/L, CiN achieved a cumulative mean estrogen removal efficiency of 66.1%. The maximum experimental uptake capacities for E1, E2, and EE2 were 3.82, 3.75, and 7.23 mg/g, respectively, yielding a notable combined capacity of 14.79 mg/g. Kinetic profiles were accurately described by the pseudo-second-order (PSO) model, which predicted an equilibrium time of 440 min at 25 °C. The multicomponent Sheindorf-Rebuhn-Sheintuch (SRS) isotherm model successfully simulated the competitive equilibrium data. Operational parameters showed that highly alkaline media (pH ≥ 12) led to a significant decline in uptake capacity due to electrostatic repulsion. Thermodynamic analysis confirmed that the sequestration process is spontaneous ( Δ G 0 < 0 ), exothermic ( Δ H 0 < 0 ), and entropically favorable ( Δ S 0 > 0 ) at the solid-liquid interface. Comprehensive mechanistic evaluation identified a synergistic interplay between physisorption via pore filling and chemisorption governed by p-electron donor-acceptor interactions and hydrogen bonding networks. The superior competitive affinity of the synthetic estrogen (EE2) was successfully rationalized by its higher hydrophobicity and lower activation energy barrier. Overall, this work highlights the viability of sustainable raw cork residues for environmental remediation, demonstrating that surface chemistry can play a more decisive role than texturized porosity in sequestering endocrine-disrupting chemicals.

PubMedBreast (Edinburgh, Scotland)2026-10-06

Prospective assessment of incomplete ovarian suppression in breast cancer using LC-MS/MS and immunoassays for estradiol.

Kelly Catherine M CM, Pusztai Lajos L, Bennett Kathleen K, Walsh Siun S et al.

During gonadotrophin-releasing hormone agonist (GnRHa) therapy some patients do not adequately suppress estradiol, termed "ovarian escape" (OE). We prospectively measured estradiol using liquid chromatography-tandem mass spectrometry (LC-MS/MS), the gold standard to determine the prevalence of OE and assess discordance with estradiol immunoassays. Patients receiving endocrine therapy plus GnRHa for ≥3 months were enrolled at two Dublin hospitals. Estradiol was measured by LC-MS/MS, Abbott Alinity i (Alinity) and Roche Cobas e 801 (Cobas) immunoassays. OE was defined as estradiol >10 pmol/L during aromatase inhibitor (AI) treatment or >77 pmol/L during tamoxifen. 94 patients enrolled, 10 had OE (11%; 95% CI 5.2-18.7%) and were younger than those without OE (40 years, IQR 38-43 versus 46 years, IQR 42-49; P < 0.005), all OE cases were receiving an AI (14%, 10/71). Exploratory multivariable logistic regression suggested increasing age was associated with lower odds of OE (OR 0.85 95% CI 0.73-0.99), BMI was not (OR 1.00, 95% CI 0.82-1.23). None of the 10 cases of OE were detected by immunoassay (sensitivity 0% both immunoassays). For Alinity and Cobas specificities were 86.5% and 100%. Seven false-positive (FP) results occurred with Alinity, including 6 patients receiving CDK4/6 inhibitors. Retesting of the 7 Alinity FP samples using Cobas demonstrated persistent FP results in 3 cases, all were receiving fulvestrant. OE occurred in 11% of women receiving GnRHa and was more common in younger women. Standard immunoassays demonstrated clinically relevant discordance compared to LC-MS/MS. These findings support LC-MS/MS for estradiol monitoring in this setting.

PubMedFrontiers in endocrinology2026-10-06

Estradiol mediates the association of waist-to-hip ratio, but not body fat percentage, with menopause-related symptoms in Chinese women aged 40-60 years.

Wang Xiaoyi X, Yang Dongjian D, Li Jiahui J, Wang Yudong Y et al.

Menopause-related symptoms adversely affect quality of life. Although both overall and central adiposity have been associated with menopausal symptoms, the role of estradiol in these associations remains unclear. This single-center cross-sectional study included 600 women aged 40-60 years who attended the International Peace Maternity and Child Health Hospital, Shanghai, China. Participants were classified into premenopausal and postmenopausal groups according to the Stages of Reproductive Aging Workshop +10 (STRAW + 10) criteria. Menopause-related symptoms were assessed using the modified Kupperman Index (KMI). Body fat percentage (PBF) and waist-to-hip ratio (WHR) were measured using a bioelectrical impedance analyzer, and serum reproductive hormone levels, including estradiol (E2), were determined by chemiluminescent immunoassay. Multivariable linear regression models were used to examine the association between body composition parameters and KMI scores. Mediation analyses were performed to evaluate the mediating role of E2, and stratified analyses by menopausal status were conducted to assess the consistency of these associations. After adjustment for potential confounders, higher WHR was independently associated with greater menopause-related symptom severity (β = 12.058, 95% CI: 1.816 to 22.300, P = 0.021), and higher PBF showed a similar association (β = 0.103, 95% CI: 0.011 to 0.196, P = 0.029). Mediation analyses revealed that E2 significantly mediated the association between WHR and KMI scores (indirect effect = 2.202, 95% CI: 0.520 to 4.323, P = 0.011; mediation proportion = 17.8%), whereas no significant mediating effect was observed for PBF (indirect effect = 0.008, 95% CI: -0.007 to 0.025, P = 0.296). Stratified analyses suggested that these associations were more evident among premenopausal women, although no significant interaction by menopausal status was observed. Both overall and central adiposity were associated with more severe menopause-related symptoms; however, estradiol mediated only the association between central adiposity and symptom severity. These findings suggest that different adiposity patterns may be associated with menopausal symptoms through distinct biological pathways.

PubMedPloS one2026-10-06

Revisiting the relation between oral contraceptive use and attentional engagement in everyday life: The role of formulation.

Smith Alyssa C AC, Smilek Daniel D

Oral contraceptives (OCs) are composed of artificial estrogen (ethinyl-estradiol) and/or progesterone (progestin), which can attach to receptors in the brain and potentially influence cognition. One prior study suggested that OC use was associated with increased mind-wandering - implying that OC use was associated with detriments to attention. In contrast, two subsequent well-powered conceptual replications of this initial finding revealed little evidence that OC use was related to increases in inattentiveness (including mind-wandering). However, these later studies collapsed across different OC formulations, which may obscure effects specific to particular formulations. In the present study, we investigated the possibility that OC formulation might differentially relate to attention-related traits. To do this, we collected trait-level reports of the tendency to experience attention related errors, attention lapses, spontaneous and deliberate mind-wandering, boredom, and flow in undergraduate females using OCs, and we collected the brand of OC used from which it was possible to derive the formulation. OC formulations differed in ethinyl-estradiol dose, progestin dose, dosing schedule, hormonal activity (or potency), and the type (or 'generation') of progestin used. We found no evidence that different OC formulations were related to differences in attention-related traits, which suggests that OC users can be treated as a homogenous group when examining trait-level attention. Comparisons of OC users (collapsing across formulation) to non-users again revealed no significant differences in trait-level attention.

PubMedAlzheimer's & dementia : the journal of the Alzheimer's Association2026-10-06

Cell-based polygenic risk scores predict clinical progression and prioritize network-based therapeutic targets in Alzheimer's disease.

Sahelijo Nathan N, Rajagopalan Priya P, Qian Lu L, Rahman Rufuto R et al.

Late-onset Alzheimer's disease (AD) exhibits substantial biological heterogeneity. We developed a framework linking cell-type-specific polygenic risk profiles to precision medicine in AD. Cell-based polygenic risk scores (cbPRSs) derived from single-nucleus RNA-seq co-expression networks were evaluated in Alzheimer's Disease Neuroimaging Initiative (ADNI) and Framingham Heart Study (FHS) cohorts. Network hubs were prioritized using a graph-based PageRank algorithm and candidate drugs were validated in human-induced pluripotent stem cell (hiPSC)-derived astrocytes. Cell-based PRS analysis identified two genetic risk axes independent of network cell-type labels: an apolipoprotein E (APOE)-concentrated axis (Ast-M2/Oli-M45) and an APOE-independent axis (Ast-M10/Oli-M50), which predicted accelerated progression to AD (hazard ratio: 1.25-2.02) and correlated with localized temporal lobe atrophy, reduced glucose metabolism, and global amyloid burden. High-risk status specifically upregulated complement C4a protein expression in postmortem brains. PageRank network analysis identified four candidate drugs targeting the APOE-containing astrocyte network. Experimental treatment with estradiol and levetiracetam significantly reduced APOE and complement C4 gene expression in hiPSC-derived astrocytes. By integrating cell-based genetic risk with network-level target prioritization, this framework enables robust patient stratification and experimental target validation.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about estradiol + levonorgestrel